Next week, David Harrison FRSC, Vice President of Medicinal Chemistry at NodThera, will be presenting alongside several #LifeSciences industry leaders at the American Chemical Society (ACS) Spring 2025 Meeting & Expo, held from 23-27 March in San Diego, CA and virtually. As part of the ‘New Advances in Small Molecule Targets in Neuroscience’ session, taking place on 27 March, David will present ‘From serendipity to study in patients: The development of #NLRP3 #inflammasome inhibitor NT-0796 for the treatment of neuroinflammation.’ This presentation will describe the journey of NT-0796, our lead brain-penetrant candidate, from discovery through to #ClinicalDevelopment in a wide range of chronic inflammatory conditions, including Parkinson’s disease. If you are also attending, be sure to stop by Room 30B from 9:20-9:45PST to learn more about our targeted approach to tackling chronic #inflammation. For more information on #ACSSpring2025: https://lnkd.in/epnuH-2f #NodThera #Networking #Conference #Biotech
NodThera
生物技术研究
Philadelphia，Pennsylvania 3,920 位关注者
Treating chronic disease by targeting inflammation at its source
关于我们
NodThera is developing a new class of potent and highly selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. We’re building a dynamic team of people across our offices in Cambridge, UK; Seattle, WA; and Boston, MA; all united by our shared ambition, enthusiasm, and creativity.
- 网站
-
https://nodthera.com
NodThera的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Philadelphia，Pennsylvania
- 类型
- 私人持股
- 创立
- 2016
地点
NodThera员工
动态
-
Meet us at BIO-Europe Spring (EBD Group) next week! We’re looking forward to connecting and exploring partnership opportunities around NodThera’s #NLRP3 #inflammasome inhibitors, tackling chronic inflammation at its source. Please reach out if you would like to connect and see you in Milan! #NodThera #BioEuropeSpring #Networking #Conference #Biotech?
-
-
On 10 March, NodThera’s management team will be on the ground in Miami to participate in 1-1 #investor meetings at the Leerink Partners 2025 Global #Healthcare Conference. This #conference offers a valuable opportunity to share our vision to transform the treatment paradigm for #cardiometabolic and #neurodegenerative diseases through the development of our cutting-edge #NLRP3 #inflammasome approach. If you would like to learn more about how our work is paving the way for next-generation therapies that address chronic #inflammation at its source, please reach out to set up a meeting. #Networking #Innovation #Biotech #Obesity #NodThera
-
-
Obesity isn’t just about excess weight—it’s a chronic inflammatory disease that fuels a cascade of cardiometabolic risks. Despite advances in obesity management, one critical factor remains overlooked: chronic low-grade inflammation, a silent driver of insulin resistance, endothelial dysfunction, and atherosclerosis. The future of obesity care lies in targeting inflammation at its core. NodThera’s #NLRP3 #inflammasome inhibitors represent a new frontier—disrupting the inflammatory cascade and addressing the root cause of obesity-related diseases, not just the symptoms. As we mark #WorldObesityDay, it's time to shift the conversation from weight loss alone to precision inflammation control. The future of obesity treatment is here—are we ready to embrace it??
-
-
Our CEO, Daniel Swisher, and CFO, Greg Chow, will be attending the 45th Annual TD Securities Healthcare Conference in Boston from 3-5 March. Dan and Greg will be hosting 1-1 investor meetings, providing an excellent opportunity to discuss our latest breakthroughs in advancing the treatment of #obesity, #cardiometabolic and #neurodegenerative diseases. If you will be at the conference and would like to learn more about our innovative #NLRP3 #inflamamsome inhibitor approach and its potential to transform patient outcomes, please get in touch! #Networking #NodThera #Neuroinflammation #inflammation
-
-
Our CEO, Daniel Swisher, recently sat down with Trinity Chavez, Lead Anchor for the New York Stock Exchange (NYSE), to discuss our plans for 2025. In this latest episode of #TakingStock, Dan shares our vision to transform the treatment of #obesity, #cardiometabolic and #neurodegenerative diseases. Our game-changing #NLRP3 #inflammasome inhibitor approach targets chronic inflammation at its source, unlocking new possibilities for patients worldwide. Dan also dives into our late-stage #ClinicalTrial plans and the innovative programs we’ll be advancing in 2025. Watch full conversation here: https://lnkd.in/ehDaDnuc #TSTC #Biotech #Inflammation #Innovation
-
Continuing the momentum after a productive J.P. Morgan #Healthcare Conference, our CEO, Daniel Swisher, will join a panel discussion at the Guggenheim Securities SMID Cap Biotech #Conference in New York City. Entitled ‘CV/MET Blockbusters Beyond Obesity: The Resurgence of Outcomes-Driven Assets in CVD and Bone Health,’ the panel will take place on 5 February from 11:00-11:55 ET. This conference brings together #biotech industry leaders, influential executives and institutional investors, and we look forward to discussing our vision to revolutionize the treatment of #cardiometabolic and #neurodegenerative diseases via our cutting-edge #NLRP3 #inflammasome-targeting approach. Please get in touch if you would like to connect. #Networking #NodThera #Neuroinflammation
-
-
We’re thrilled to share this wonderful post about Alan Watt’s recent lecture at ESCP’s London Campus! Alan’s impressive career and his passion for mentorship and innovation continue to inspire the next generation of biotech leaders. As President & CSO at NodThera, Alan’s groundbreaking work in #inflammasome inhibitors is paving the way for new treatments in inflammatory and neuroinflammatory diseases. His ability to drive projects from concept to clinical stage while securing the required funding is nothing short of remarkable! The lecture also highlighted his journey through significant roles at Cellzome, GlaxoSmithKline, and Merck, offering invaluable lessons in leadership, resilience, and adaptability in the ever-evolving biotech and pharmaceutical industries. Thank you, Alan, for your continued contributions to the field and for sharing your insights with future leaders. Your commitment to innovation, education, and mentorship is truly inspiring!
Ingénieur Biotechnologies - MSc Management Pharmaceutique et des Biotechnologies | ESCP Business School - Futur Professionnel en Fusions-Acquisitions en Biotechnologies
? Insightful Lecture with Alan Watt at ESCP’s London Campus! ? On December 17th, we had the privilege of attending a compelling lecture with Alan Watt, an industry leader with an impressive career in the biotech and pharmaceutical sectors. Alan’s experiences across leadership, scientific, and executive roles provided invaluable lessons for all of us. ?? Highlights of Alan Watt’s Career and the Lecture: ?? A Diverse and Impactful Career: Alan is currently President & CSO at NodThera, a biotech company focusing on inflammasome inhibitors for treating inflammatory and neuroinflammatory diseases. His leadership at NodThera spans roles as CEO and CSO, helping secure over $100M in funding and driving projects to clinical stages. ?? Executive Leadership and Innovation: Before NodThera, Alan held significant positions including: ? Vice President, Therapeutics at Cellzome – Leading drug discovery and development until the company’s acquisition by GSK. ? Vice President and Director at GlaxoSmithKline – Overseeing preclinical development and leading innovation in drug discovery. ? Senior Director at Merck Sharp and Dohme – Heading the Drug Metabolism and Pharmacokinetics department for 20+ years. ?? Commitment to Education and Mentorship: Alan has been a Visiting Lecturer at ESCP Business School since 2017, sharing his vast knowledge and inspiring future leaders in pharma and biotech. ?? Key Takeaways from the Lecture: ? Resilience and Adaptability: Alan emphasized the need to adapt and evolve continuously in a fast-changing industry. ? Visionary Leadership: Building and maintaining long-term strategies while remaining innovative is crucial for success. ? Mentorship and Lifelong Learning: Alan highlighted the importance of seeking mentors and staying curious throughout one’s career. His journey is a testament to perseverance, passion, and the ability to lead with purpose. This session left us all with a renewed sense of direction and inspiration for our future careers. A huge thank you to Alan Watt for sharing his incredible journey and insights with us. Your guidance is truly invaluable! Irié Carel,Romane Clarke,Laura Lacombe Ossó,Elisabeth Songue. DMD. #ESCP #Leadership #Biotech #CareerGrowth #Pharma #Mentorship
-
-
Our CEO, Daniel Swisher will be participating in panel discussion alongside several leading #BioPharma experts at Sachs Associates' 1st Annual Biopharma Obesity Innovation Forum, held on 11 January at the Marines’ Memorial Club in San Francisco and online. The panel, ‘BioPharma Dealmaking: Building the Pipeline,’ will explore the key trends and strategies that are shaping the #obesity treatment space, with a focus on emerging challenges and opportunities, including how to effectively build and manage a pipeline with the potential to transform patient outcomes. In the event you are not able to attend, a recording of the panel session will be available on demand the week following #JPM2025. For more information and to register for #Sachs_BOIF: https://lnkd.in/ek4TSW6j #Conference #Biotech #NLRP3 #Inflammasome #Inflammation
-
-
Our management team will be attending the J.P. Morgan 43rd Annual Healthcare Conference, from 13-16 January in San Francisco. The conference offers a valuable opportunity for one-on-one meetings, as we share NodThera’s innovative approach to tackling chronic inflammation. Get in touch to discuss how we can drive meaningful advances in patient health and treatment. #Networking #NodThera #NLRP3 #Biotech #Conference #JPMHC25
-